Predictive performance of the 2010 ACR/EULAR classification criteria
| Study (LoE) | Outcome to be predicted by the criteria at baseline | Population | Sens | Spec | PPV | NPV | Multivariable OR (95% CI) |
|---|---|---|---|---|---|---|---|
| Alves et al (2b)86 | Use of MTX at 1 year | EA (n=231) | 74 | 66 | 76 | 63 | NR |
| Britsemmer et al (2b)87 | EA (n=455) | 85 | 50 | 86 | 63 | NR | |
| Berglin and Dahlqvist (2b)91 | EA (n=313) | 84 | 54 | NR | NR | NR | |
| Cader et al (2b)88 | Use of DMARDs at 1 year | EA (n=205) | 62 | 78 | 75 | 66 | NR |
| Varache et al (2b)89 | EA (n=143) | 51 | 90 | 75 | 76 | NR | |
| van der Linden et al (2b)45 | EA (n=2258) | 74 | 74 | NR | NR | NR | |
| Reneses et al (1b)90 | EA (n=201) | 75 | 73 | NR | NR | NR | |
| Biliavska et al (2b)92 | EA (n=303) | 80 | 61 | 82 | 71 | NR | |
| Ravindran et al (1b)93 | EA (n=134) | 97 | 93 | 99 | 77 | NR | |
| Tamai et al (1b)95 | EA (n=166) | 62 | 83 | 83 | 61 | NR | |
| Combe et al (2b)75 | Use of DMARDs at 5 years | EA (n=813) | NR | NR | NR | NR | 2.5 (1.6 to 4.0) |
| Le Loët et al (2b)96 | Erosive disease at 2 years | EA (n=269) | 100 | 36 | 11 | 100 | NR |
| Britsemmer et al (2b)87 | Erosive disease at 3 years | EA (n=455) | 91 | 21 | 22 | 91 | NR |
| Mäkinen et al (2b)94 | Erosive disease at 10 years | EA (n=221) | 87 | 44 | 68 | 72 | NR |
NPV and PPV are presented in percentages.
DMARDs, disease-modifying antirheumatic drugs; EA, early arthritis; LoE, level of evidence; MTX, methotrexate; NPV, negative predictive value; NR, not reported; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.